Sentinel Lymph Node Biopsy for Melanoma: Indications, Technique, and What Results Mean

The Bottom Line

A sentinel lymph node (SLN) biopsy is the gold-standard test for determining whether melanoma has begun to spread to your lymph nodes. It is minimally invasive, typically done alongside your main melanoma surgery, and identifies hidden spread in 25-30% of patients with intermediate-thickness melanoma (0.8-4 mm). If cancer is found in the sentinel node, your stage changes to Stage III, which qualifies you for additional treatments that cut recurrence risk by 25-30%. If no cancer is found, that is a strong reassuring sign with excellent long-term odds.

What Is a Sentinel Lymph Node Biopsy?

When melanoma grows past its early stage, cells can break away and travel through your lymphatic system—a network of vessels and glands that runs throughout your body. The first lymph node to receive drainage from the tumor site is called the sentinel node (from the Latin word for “guard”).

A sentinel lymph node biopsy is a surgical procedure where your team identifies and removes that first sentinel node (or a small cluster of 1-3 nodes) and sends it to a pathologist for detailed microscopic examination. The logic is straightforward: if melanoma cells haven't reached the sentinel node yet, they almost certainly haven't reached any further lymph nodes either. If cells are found there, the sentinel node has “caught” the early spread.

This is the most sensitive staging tool available. In patients with melanomas 0.8-4 mm thick, SLN biopsy detects hidden spread in 25-30% of cases—patients who would otherwise appear to have localized disease but actually have Stage III disease and need additional treatment.

Who Needs This Procedure?

Your melanoma's thickness (Breslow depth) is the primary factor driving the recommendation:

  • Breslow 0.8-4 mm: Standard recommendation for SLN biopsy. This is where the procedure provides the most useful information.
  • Breslow under 0.8 mm with high-risk features: Ulceration, mitotic rate of 1+ per mm², deep invasion (Clark level IV-V), or patient age under 40 may justify SLN biopsy even at thin depths.
  • Breslow over 4 mm: These thick melanomas have a 40-50% chance of nodal spread. SLN biopsy still provides staging information, though some cases proceed directly to completion node dissection.

The procedure is generally not done during pregnancy (radioactive tracer is contraindicated) but can be safely deferred until after delivery. Prior surgery or radiation in the relevant nodal basin may make the procedure more technically challenging.

Understanding Your Risk of a Positive Result

The risk of finding cancer in the sentinel node rises with tumor thickness:

  • Breslow 0.8-1.0 mm: about 5% chance of positive SLN
  • Breslow 1.01-2.0 mm: about 15-20% chance
  • Breslow 2.01-4.0 mm: about 30-40% chance
  • Breslow over 4.0 mm: about 40-50% chance

Ulceration and a high mitotic rate further increase these percentages. Your surgeon will review these numbers with you to help weigh the decision.

How the Procedure Works

Preoperative Lymphatic Mapping

The day before or the morning of surgery, a small amount of radioactive tracer (technetium-99m sulfur colloid) is injected around the original melanoma site. Nuclear medicine imaging then maps exactly which lymph node basin(s) the tracer flows to—groin, armpit, or neck, depending on where your melanoma was located. This image guides your surgeon precisely.

Blue Dye Injection

In the operating room, your surgeon injects a blue or green dye around the melanoma site just before the procedure begins. This dye travels visibly through the lymphatic vessels and stains the sentinel node(s) blue, serving as a secondary confirmation.

Locating and Removing the Sentinel Nodes

Using a handheld gamma probe (a device that detects radioactivity), your surgeon identifies the hottest spot in the nodal basin corresponding to the sentinel node. The blue staining confirms it visually. A small incision is made, and the 1-3 sentinel nodes are removed. The surrounding lymph nodes are left entirely in place.

Pathology Examination

The removed sentinel nodes go to the pathology lab, where they are cut into very thin serial sections throughout the entire node. Multiple types of staining are used:

  • Standard hematoxylin-eosin staining on multiple sections
  • Immunohistochemistry using melanoma-specific markers (S100, Melan-A/MART-1, HMB-45, SOX10) to detect even tiny clusters of cells
  • In some centers, molecular testing (RT-PCR) for additional sensitivity

This thorough process can detect micrometastases (tiny cancer deposits 0.1-2 mm) that would be missed by standard pathology alone.

Interpreting Your Results

Negative Result: No Cancer Found

The sentinel node(s) are free of melanoma cells. This is highly reassuring. A negative SLN means you almost certainly don't have regional spread, and your prognosis is significantly better than for node-positive patients:

  • Stage I (thinner tumors, node-negative): 10-year survival over 90%
  • Stage II (thicker tumors, node-negative): 10-year survival of 60-85% depending on tumor characteristics

You will typically continue with surveillance rather than systemic treatment.

Positive Result: Cancer Cells Found

Melanoma cells were detected in one or more sentinel nodes. You are now staged as Stage III. The prognosis depends on the amount of cancer found:

  • Stage IIIA (occult micrometastasis, smallest deposits): 5-year survival approximately 60-75%
  • Stage IIIB (more extensive nodal disease): approximately 50-59%
  • Stage IIIC (multiple nodes involved): approximately 20-40%

A positive result changes your treatment plan substantially, and there are now effective options that significantly improve your odds.

Treatment After a Positive SLN Biopsy

Observation vs. Completion Lymph Node Dissection

Previously, a positive SLN routinely meant removing all remaining lymph nodes in that region (called a completion lymph node dissection, or CLND). The landmark MSLT-II trial showed that for patients with limited SLN disease, surveillance with ultrasound imaging produces equivalent overall survival to CLND—while sparing patients from the significant side effects of removing all nodes (lymphedema, nerve injury, infection). Today, observation is the preferred approach for most patients with positive SLN. CLND is reserved for patients with clinically obvious nodal disease or extensive sentinel node involvement.

Adjuvant Immunotherapy

All Stage III (SLN-positive) patients should discuss adjuvant immunotherapy with their oncologist. Pembrolizumab (Keytruda) or nivolumab (Opdivo) given for about 1 year after surgery improves recurrence-free survival from roughly 50% to 70% at 3 years—a meaningful difference. These are the same checkpoint inhibitor drugs used to treat metastatic melanoma.

Targeted Therapy for BRAF-Mutant Melanoma

If your melanoma has a BRAF V600E mutation (found in about 60% of melanomas), dabrafenib plus trametinib is an alternative adjuvant option. Your oncologist will discuss which approach or sequence is most appropriate for your specific situation.

When to See a Dermatologist or Surgeon

  • You have been diagnosed with melanoma and your Breslow depth is 0.8 mm or greater
  • You want to understand whether SLN biopsy is recommended for your specific melanoma
  • You had a positive SLN result and want to understand your next steps
  • You need a referral to a surgical oncologist who performs this procedure
  • You have questions about adjuvant therapy options after SLN biopsy

Frequently Asked Questions

Is the sentinel node biopsy surgery risky?

Sentinel lymph node biopsy is a well-established, low-risk procedure. Complications are much less common than with complete lymph node dissection and include a small risk of wound infection, temporary skin discoloration from the blue dye (which fades over time), mild bruising, and rarely, numbness near the incision. The radioactive tracer used is a very small amount with minimal radiation exposure—far less than a standard CT scan. Most patients have the procedure under general anesthesia and go home the same day.

What if the sentinel node is negative but cancer comes back later?

A negative SLN is highly reassuring but not a 100% guarantee that no cancer has spread. Rarely, patients with a negative SLN develop subsequent nodal or distant recurrence—called a false negative. Studies show false-negative rates of about 5-10%. This is why ongoing surveillance visits and imaging continue after surgery, even with a negative result.

Do I still need surgery if my SLN biopsy is positive?

A positive SLN biopsy by itself does not necessarily mean you need a complete lymph node dissection. As described above, the MSLT-II trial showed that imaging surveillance is equivalent in terms of overall survival for most patients. You will need ongoing ultrasound monitoring of the affected nodal basin. Your surgeon will discuss the specific recommendation based on how much cancer was found in the sentinel node.

Can melanoma spread without going through the lymph nodes?

Yes. Melanoma can spread through both lymphatic vessels (to nearby lymph nodes) and blood vessels (to distant organs). A negative SLN biopsy addresses lymphatic spread, but distant spread via blood vessels can still occur independently. This is why surveillance with periodic imaging (CT or PET scans) is recommended for higher-risk patients even after a negative SLN result.

References

  1. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599-609.
  2. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma (MSLT-II). N Engl J Med. 2017;376(23):2211-2222.
  3. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
  4. Weber JS, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma (CheckMate 238). N Engl J Med. 2017;377(19):1824-1835.
  5. Eggermont AM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (KEYNOTE-054). N Engl J Med. 2018;378(19):1789-1801.
  6. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.

Trusted Resources

Always consult a board-certified dermatologist or surgical oncologist for personalized advice about your melanoma staging and treatment options.